Table 3.
Clinical trials of ICIs plus epigenetic agents.
| Cancer Type | Targeted Agents | Combination Agents | Phase | Control | Primary Endpoint | NCT Number |
|---|---|---|---|---|---|---|
| Uveal Melanoma | Entinostat | Pembrolizumab | II | - | ORR: 14% (95% CI 3.9–31.7) | NCT02697630 |
| AML | Azacitidine | Nivolumab | II | - | ORR: 33% | NCT02397720 |
| Hodgkin Lymphoma | Decitabine | Camrelizumab | II | - | ORR: 60% (95% CI 45–74) | NCT02961101 |
Source: http://www.clinicaltrials.gov (accessed on 29 July 2022). AML, acute myeloid leukemia; CI, confidence interval; ORR, objective response rate.